To further explore the hypothesis that immune reactivity directed toward RFX4 is relevant to narcolepsy pathophysiology and hypocretin cell loss, we searched for autoantibodies directed against RFX4_v1/v3/v4 in 86 T1N patients and 88 controls using high throughput flow cytometry-based (FACS) staining assays and explored T cell reactivity to RFX4 peptides bound to DQ0602. This evidence concerns the gene RFX4 and narcolepsy.